HI
ACAD icon

HBK Investments’s Acadia Pharmaceuticals ACAD Stock Holding History

HBK Investments’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-33,700
Closed -$1.11M – 951
2015
Q3 		$1.11M Buy
+33,700
New +$1.4M 0.01% 563

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

HBK Investments's ACAD Position: Q4 2015 in Review

HBK Investments sold out of Acadia Pharmaceuticals (ACAD) in Q4 2015, closing a stake of 33,700 shares — an estimated $1.11M sold.

HBK Investments first reported a position in ACAD in Q3 2015 and held it in 1 quarter. The position peaked at $1.11M in Q3 2015. 215 funds tracked by Wall St. Rank hold ACAD as of Q4 2015.

  • HBK Investments reported no remaining Acadia Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • HBK Investments sold 33,700 Acadia Pharmaceuticals shares in Q4 2015, an estimated $1.11M.
  • HBK Investments first reported a position in Acadia Pharmaceuticals in Q3 2015 and held it in 1 quarter.
  • HBK Investments's Acadia Pharmaceuticals position peaked at $1.11M in Q3 2015.
  • 215 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2015.

Based on HBK Investments's 13F filing for Q4 2015, filed 16 Feb 2016.